Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018-Reference-Cited by-同舟云学术

Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018

Published:2022-06-23 Issue:8 Volume:39 Page:3711-3734
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Liu Yifei^ORCID,Skup Martha,Yang Min,Qi Cynthia Z.,Wu Eric Q.

Funder

AbbVie

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02173-7.pdf

Reference119 articles.

1. Biosimilars Resource Center. What are biologics? 2017. https://www.biosimilarsresourcecenter.org/faq/what-are-biologics/. Accessed 16 Oct 2020.

2. Feldman SR, Bagel J, Namak S. Biosimilars for immune-mediated chronic diseases in primary care: what a practicing physician needs to know. Am J Med Sci. 2018;355:411–7.

3. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27:55–62.

4. Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015;21:s331–40.

5. Chingcuanco F, Segal JB, Kim SC, Alexander GC. Bioequivalence of biosimilar tumor necrosis factor-alpha inhibitors compared with their reference biologics: a systematic review. Ann Intern Med. 2016;165:565–74.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?;Journal of Health Economics and Outcomes Research;2024-03-25

2. Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?;Journal of Health Economics and Outcomes Research;2024-03-25

3. Modeling the Effects of Formulary Exclusions: How Many Patients Could Be Affected by a Specific Exclusion?;2023-11-07

4. Health Care Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar;ACR Open Rheumatology;2023-10

5. Correction to: Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018;Advances in Therapy;2022-08-30